Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS: ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients received up to ten 21-day cycles of doc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Crabb, Simon J., Griffiths, Gareth, Marwood, Ellice, Dunkley, Denise, Downs, Nichola, Martin, Karen, Light, Michelle, Northey, Josh, Wilding, Sam, Whitehead, Amy, Shaw, Emily, Birtle, Alison J., Bahl, Amit, Elliott, Tony, Westbury, Charlotte, Sundar, Santhanam, Robinson, Angus, Jagdev, Satinder, Kumar, Satish, Rooney, Claire, Salinas-Souza, Carolina, Stephens, Christine, Khoo, Vincent, Jones, Robert J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078455/
https://ncbi.nlm.nih.gov/pubmed/33326257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01576
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares